For patients with ER/PR+ ABC previously treated with 1–2 lines of chemotherapy, TROPION-Breast01 (NCT05104866) randomized patients to receive Dato-DXd 6 mg/kg IV every 3 weeks or ICC or TPC (eribulin mesylate, capecitabine, vinorelbine, or gemcitabine) [31]. The gene discussed is ESR1; the disease is intrahepatic cholangiocarcinoma.